12.01
-0.40 (-3.22%)
| Previous Close | 12.41 |
| Open | 12.06 |
| Volume | 650,331 |
| Avg. Volume (3M) | 937,515 |
| Market Cap | 935,708,608 |
| Price / Earnings (Forward) | 5.30 |
| Price / Sales | 0.580 |
| Price / Book | 0.930 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | -1.78% |
| Operating Margin (TTM) | 8.23% |
| Diluted EPS (TTM) | -0.380 |
| Quarterly Revenue Growth (YOY) | 3.70% |
| Quarterly Earnings Growth (YOY) | -2.00% |
| Total Debt/Equity (MRQ) | 132.59% |
| Current Ratio (MRQ) | 1.21 |
| Operating Cash Flow (TTM) | 102.37 M |
| Levered Free Cash Flow (TTM) | 35.55 M |
| Return on Assets (TTM) | 2.66% |
| Return on Equity (TTM) | -1.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Integra LifeSciences Holdings C | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.38 |
|
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 14.23% |
| % Held by Institutions | 96.47% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rubric Capital Management Lp | 30 Sep 2025 | 7,653,934 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 13.00 (JP Morgan, 8.24%) | Sell |
| 13.00 (Truist Securities, 8.24%) | Hold | |
| Median | 13.00 (8.24%) | |
| Low | 11.00 (Citigroup, -8.41%) | Sell |
| Average | 12.33 (2.66%) | |
| Total | 1 Hold, 2 Sell | |
| Avg. Price @ Call | 11.84 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 03 Nov 2025 | 13.00 (8.24%) | Hold | 11.49 |
| Citigroup | 31 Oct 2025 | 11.00 (-8.41%) | Sell | 12.01 |
| JP Morgan | 31 Oct 2025 | 13.00 (8.24%) | Sell | 12.01 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Jan 2026 | Announcement | Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 01 Dec 2025 | Announcement | Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference |
| 25 Nov 2025 | Announcement | Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access |
| 11 Nov 2025 | Announcement | Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries |
| 30 Oct 2025 | Announcement | Integra LifeSciences Reports Third Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |